Qing Zhou, MD – Guangdong Lung Cancer Institute
Preliminary data from a phase I/II study of KL590586, a next-generation selective RET inhibitor, show promising results in patients with RET-altered solid tumors. The drug demonstrated good tolerability and substantial clinical activity, including in non-small cell lung cancer (NSCLC) patients with resistance to first-generation inhibitors and those with brain metastases. These findings support the advancement of KL590586 to pivotal studies for further evaluation.